2nd Quarter of Fiscal Year 2026 (Ending March 31, 2027)
(April 1, 2026 to September 30, 2026)

Supplementary Materials
(Consolidated IFRS)

ONO PHARMACEUTICAL CO., LTD.

Contents

【Consolidated Financial Results for the 2nd Quarter of Fiscal Year 2026 (Ending March 31, 2027) (Core basis)】

Page 1	Sales Revenue Result and Forecast of Major Products
	Details of Sales Revenue, Revenue by Geographic Area
Page 2	Consolidated Financial Forecast for FY 2026 (April 1 2026 to March 31, 2027) (Core basis)
Page 3	Depreciation and Amortization, Capital Expenditure and Investments on Intangible Assets
	Number of Employees
Page 4	Status of Shares
Page 5~9	Main Status of Development Pipelines
Page 10~11	Profile for Main Development

Note: “(Billions of yen)” are rounded.

Sales Revenue Result and Forecast of Major Products

(Billions of Yen)

Product Name	Six months ended September 30, 2026 (April 1, 2026 to September 30, 2026)					FY 2026 Forecast (April 1, 2026 to March 31, 2027)		
	Cumulative			YoY		Forecast	YoY	
	Apr ~ Jun	Jul ~ Sep		Change	Change (%)		Change	Change (%)
<Domestic>								
Opdivo Intravenous Infusion	28.2	29.0	**57.2**	(1.3)	(2.3%)	**120.0**	5.7	5.0%
Orencia for Subcutaneous Injection	4.8	4.8	**9.6**	(4.2)	(30.5%)	**19.0**	(7.6)	(28.6%)
Velexbru Tablets	3.2	3.0	**6.1**	0.1	1.6%	**12.0**	0.1	0.9%
Parsabiv Intravenous Injection	2.4	2.6	**5.0**	0.5	11.3%	**10.0**	1.0	11.2%
Ongentys Tablets	2.6	2.6	**5.2**	0.8	17.0%	**10.0**	1.0	11.5%
Glactiv Tablets	3.1	3.1	**6.2**	(0.7)	(10.1%)	**9.5**	(3.7)	(28.1%)
Braftovi Capsules	2.0	2.0	**4.0**	1.3	50.1%	**8.5**	2.9	51.5%
Kyprolis for Intravenous Infusion	1.8	1.7	**3.5**	(0.5)	(12.3%)	**7.0**	(0.5)	(6.6%)
<Overseas>								
QINLOCK®	11.7	11.0	**22.8**	4.6	25.6%	**43.0**	4.6	12.1%
ROMVIMZA™	4.1	4.6	**8.7**	5.9	215.8%	**19.0**	10.7	129.4%
Opdivo	3.5	3.7	**7.2**	(0.0)	(0.3%)	**13.0**	(1.2)	(8.2%)

Notes: 1. Sales revenue of domestic products is shown in a gross sales basis (shipment price).
2. Sales revenue of overseas products is shown in a net sales basis.

Details of Sales Revenue

(Billions of yen)

	Six months ended September 30, 2025	**Six months ended September 30, 2026**
Revenue of goods and products	175.0	**136.1**
Royalty and others	82.2	**96.4**
Total	257.1	**232.5**

Note: In "Royalty and others", royalty revenue from Opdivo by Bristol-Myers Squibb Company is included, amounting to ¥59.4 billion for the second quarter (six months) ended September 30, 2025, and ¥69.1 billion for the second quarter (six months) ended September 30, 2026. In addition, royalty revenue from Keytruda® by Merck & Co., Inc. is included, amounting to ¥13.8 billion for the second quarter (six months) ended September 30, 2025, and ¥16.1 billion for the second quarter (six months) ended September 30, 2026.

Revenue by Geographic Area

(Billions of yen)

	Six months ended September 30, 2025	**Six months ended September 30, 2026**
Japan	148.8	**98.8**
USA	93.5	**115.8**
Asia	8.9	**8.9**
Europe	5.1	**8.2**
Others	0.8	**0.8**
Total	257.1	**232.5**

Note: Revenue by geographic area is presented on the basis of the place of customers.

Consolidated Financial Forecast for FY 2026 (April 1, 2026, to March 31, 2027) (Core Basis)

Consolidated Financial Forecast

(Billions of yen)

	FY 2025 (April 1, 2025 to March 31, 2026)	**FY 2026 (April 1, 2026 to March 31, 2027)**	YoY
Revenue	515.8	**455.0**	(11.8%)
Core operating profit	137.1	**124.0**	(9.6%)
Core profit for the year (attributable to owners of the Company)	103.5	**93.0**	(10.1%)

Details of Sales Revenue (Forecast)

(Billions of yen)

	FY 2025 (April 1, 2025 to March 31, 2026)	**FY 2026 Forecast (April 1, 2026 to March 31, 2027)**
Revenue of goods and products	342.6	**270.0**
Royalty and others	173.2	**185.0**
Total	515.8	**455.0**

1. Revenue ¥455.0 billion YoY a decrease of ¥60.8 billion (11.8%)

- Revenue of goods and products are expected to be ¥270.0 billion, a decrease of ¥72.6 billion (21.2%) year on year, mainly due to the absence of sales of Forxiga Tablets following the termination of the co-promotion agreement with AstraZeneca, despite continued growth in prescriptions of Opdivo Intravenous Infusion, QINLOCK, a treatment for gastrointestinal stromal tumors, and ROMVIMZA, a treatment for tenosynovial giant cell tumor (TGCT).
- Royalty and others are expected to increase by ¥11.8 billion (6.8%) year on year to ¥185.0 billion, mainly due to increased royalty income from Bristol-Myers Squibb Company and other partners.
- Revenue is therefore expected to be ¥455.0 billion, a decrease of ¥60.8 billion (11.8%) year on year.

2. Core Operating profit ¥124.0 billion YoY a decrease of ¥13.1 billion (9.6%)

- Cost of sales is expected to be ¥84.0 billion, a decrease of ¥23.0 billion (21.5%) year on year, mainly due to the decrease in sales following the termination of the co-promotion agreement for Forxiga Tablets.
- Research and development costs are expected to be ¥143.0 billion, a decrease of ¥2.1 billion (1.5%) year on year. The Company will continue proactive R&D investments, exceeding 30% of net sales, including the conduct of global clinical trials for compounds such as sapablursen and ONO-4578.
- Selling, general, and administrative expenses (except for research and development costs) are expected to be ¥101.0 billion, a decrease of ¥22.6 billion (18.3%) year on year, mainly due to a reduction in co-promotion expenses associated with the termination of the co-promotion agreement for Forxiga Tablets.
- Therefore, core operating profit is expected to be ¥124.0 billion, a decrease of ¥13.1 billion (9.6%) year on year.

3. Core profit for the year ¥93.0 billion YoY a decrease of ¥10.5 billion (10.1%) (attributable to owners of the Company)

- Core profit attributable to owners of the Company is expected to be ¥93.0 billion, a decrease of ¥10.5 billion (10.1%) year on year.

Depreciation and Amortization, Capital Expenditure and Investments on Intangible Assets

Depreciation and Amortization

(Billions of yen)

	FY 2025 (April 1, 2025 to March 31, 2026)	**FY 2026 2Q YTD (April 1, 2026 to September 30, 2026)**	**FY 2026 Forecast (April 1, 2026 to March 31, 2027)**
Property, plant, and equipment	10.6	**5.3**	**11.0**
Intangible assets	27.2	**12.7**	**25.1**
Total	37.8	**18.1**	**36.2**
Ratio to sales revenue	7.3%	**7.8%**	**8.0%**

Capital Expenditure (Based on Constructions) and Investments on Intangible Assets

(Billions of yen)

	FY 2025 (April 1, 2025 to March 31, 2026)	**FY 2026 2Q YTD (April 1, 2026 to September 30, 2026)**	**FY 2026 Forecast (April 1, 2026 to March 31, 2027)**
Property, plant, and equipment	7.9	**3.6**	**10.2**
Intangible assets	47.1	**6.2**	**18.8**
Total	55.0	**9.8**	**29.0**

Number of Employees (Consolidated)

	FY 2025 2Q (as of September 30, 2025)	FY 2025 (as of March 31, 2026)	**FY 2026 2Q (as of September 30, 2026)**
Number of employees	4,276	4,206	**4,207**

Status of Shares (as of September 30, 2026)

Number of Shares

	As of September 30, 2026
Total number of authorized shares	1,500,000,000
Number of shares issued and outstanding	498,692,800

Number of Shareholders

	As of September 30, 2026
Number of shareholders	103,789


Principal Shareholders

(As of September 30, 2026)

Name of shareholder	Number of shares held (Thousands of shares)	Shareholding percentage
The Master Trust Bank of Japan, Ltd. (Trust account)	62,697	13.10
Custody Bank of Japan, Ltd. (Trust account)	21,820	4.56
Meiji Yasuda Life Insurance Company	18,594	3.88
Ono Scholarship Foundation	16,428	3.43
KAKUMEISOU Co., LTD.	16,158	3.37
JP Morgan Securities Japan Co., Ltd	12,795	2.67
STATE STREET BANK AND TRUST COMPANY 505001	8,716	1.82
MUFG Bank, Ltd.	8,640	1.80
The Master Trust Bank of Japan, Ltd. (Stock Grant ESOP Trust Account 80358)	8,398	1.75
STATE STREET BANK AND TRUST COMPANY 505103	6,602	1.37

Notes: 1. The Company is excluded from the principal shareholders listed in the table above, although the Company holds 20,187 thousand shares of treasury share.
2. The shareholding percentage is calculated by deducting treasury share (20,187 thousand shares).

Ownership and Distribution of Shares



Note: The ratio by shareholders listed above is rounded down to two decimal places. Therefore, their total does not amount to 100%.

Main Status of Development Pipelines

As of October 29, 2026, we have listed our pipeline, which includes projects that we are developing clinically either independently (including through our wholly-owned subsidiaries) or in collaboration with partners, as well as those for which we hold contractual rights for potential future clinical development and/or commercialization. Please note that this does not encompass all development activities.

- For regions where we have obtained marketing approval for any indication, the product name is also listed.
- The development stage is indicated for the main countries/regions where we hold rights.
- The start date for clinical trials is based on the date of acceptance of the clinical trial notification, unless otherwise specified.
- Regarding in-house/in-license products, those in which the Ono Group was involved in the drug discovery process during joint research are considered in-house, while those for which we hold commercialization rights are considered in-license. For limited rights, the specific countries/regions are listed separately.

(Oncology)

Development code Generic name Product name (Dosage form)	Pharmacological Action	Target indication (Combination drug)	Phase	In-house / In-license
ONO-4538 Nivolumab Opdivo (Intravenous injection)	A human anti-human PD-1 monoclonal antibody	Anaplastic thyroid cancer (Combination with lenvatinib)	Filed (Japan) 26/06	In-house (Co-development with Bristol-Myers Squibb)
		Non-small cell lung cancer, Neoadjuvant and adjuvant therapy (Combination with chemotherapy)	Approved (South Korea, Taiwan)26/08, P3	In-house (Co-development with Bristol-Myers Squibb)
		Rhabdoid tumor, Second-line treatment	P2	In-house (Co-development with Bristol-Myers Squibb)
		Richter transformation, Second-line treatment	P2	In-house (Co-development with Bristol-Myers Squibb)
DCC-2618 ripretinib QINLOCK (Oral medication)	KIT inhibitor	Gastrointestinal stromal tumor (GIST), fourth-line treatment	Approved (South Korea) 26/10 Filed (Japan) 26/03, P1	In-house
		Gastrointestinal stromal tumor, Second-line treatment for patients with KIT exon 11+17/18 mutation	P3	In-house
ONO-4059 Tirabrutinib Hydrochloride Velexbru (Oral medication)	BTK (Bruton's tyrosine kinase) inhibitor	Primary central nervous system lymphoma, Second-line treatment and beyond	Filed (USA) 25/12	In-house
		Central nervous system infiltration of malignant lymphoma (limited to cases where existing treatments are ineffective or inappropriate)	Filed (Japan) 26/06	In-house
		Primary central nervous system lymphoma, Second-line treatment and beyond	P3	In-house
		Primary central nervous system lymphoma, First-line treatment	P2	In-house

Development code Generic name Product name (Dosage form)	Pharmacological Action	Target indication (Combination drug)	Phase	In-house / In-license
ONO-0530 sapablursen (Subcutaneous injection)	TMPRSS6 gene expression inhibitor (Oligonucleotide)	Polycythemia vera	P3	In-license (Ionis Pharmaceuticals, Inc)
ONO-4578 (Oral medication)	Prostaglandin receptor (EP4) antagonist	Gastric cancer, First-line treatment (Standard treatment (combination with Opdivo and chemotherapy))	P3	In-house
		Colorectal cancer, First-line treatment (combination with Opdivo and standard treatment)	P2	In-house
ONO-4482 relatlimab (Intravenous injection)	Anti-LAG-3 antibody	Melanoma, Second-line treatment and beyond (Combination with Opdivo)	P1/2	In-license (Japan, South Korea, Taiwan) (Co-development with Bristol-Myers Squibb)
ONO-7427 (Intravenous injection)	Anti-CCR8 antibody	Solid tumor (Combination with Opdivo)	P1/2	In-license (Japan, South Korea, Taiwan) (Co-development with Bristol-Myers Squibb)
DCC-3116 inlexisertib (Oral medication)	ULK inhibitor	Advanced malignancies (Combination with ripretinib)	P1/2	In-house
DCC-3009 (Oral medication)	Pan-KIT inhibitor	Gastrointestinal stromal tumor	P1/2	In-house
ONO-4538HSC (Subcutaneous injection)	A human anti-human PD-1monoclonal antibody	Pediatric malignant solid tumors, epithelioid sarcoma	P1/2	In-license (Japan, South Korea, Taiwan) (Co-development with Bristol-Myers Squibb)
		Solid tumor	P1	In-license (Japan, South Korea, Taiwan) (Co-development with Bristol-Myers Squibb)
DCC-2812 (Oral medication)	GCN2 activator	Renal cell carcinoma, urothelial carcinoma, castration-resistant prostate cancer	P1	In-house
ONO-4685 besufetamig (Intravenous injection)	PD-1 x CD3 bispecific antibody	T-cell lymphoma, Second-line treatment	P1	In-house
ONO-8250 (Intravenous injection)	iPS cell-derived HER2-targeted CAR-T cell therapeutics	HER2-expressing solid tumors	P1	In-house (Co-development with Fate Therapeutics, Inc.)
ONO-7428 (Intravenous injection)	Anti-ONCOKINE-1 antibody	Solid tumor	P1	In-license (NEX-I, Inc.)
ONO-7429 (Intravenous injection)	Anti-L1CAM ADC	Solid tumor	P1	In-license (LigaChem Biosciences, Inc.)

(Areas Other than Oncology)

Development code Generic name Product name （Dosage form）	Pharmacological Action	Target indication (Combination drug)	Phase	In-house / In-license
ONO-2017 Cenobamate Excopri (Oral medication)	Inhibition of voltage-gated sodium currents/positive allosteric modulator of $GABA_A$ ion channel	Partial-onset seizures	Filed (Japan) 25/09 Approved(Japan) 26/09	In-license (Japan) (SK Biopharmaceuticals)
		Partial-onset seizures (Pediatric)	P3	In-license (Japan) (SK Biopharmaceuticals)
		Primary generalized tonic-clonic seizures	P3	In-license (Japan) (SK Biopharmaceuticals)
ONO-4059 Tirabrutinib hydrochloride Velexbru （Oral medication）	BTK (Bruton's tyrosine kinase) inhibitor	Steroid-resistant pemphigus	P3	In-house
ONO-8531 povetacicept (Subcutaneous injection)	BAFF/APRIL dual antagonist	Immunoglobulin A nephropathy (IgAN)	P3	In-license (Japan, South Korea) (Vertex Pharmaceuticals Incorporated)
		Membranous nephropathy	P2b/3	In-license (Japan, South Korea) (Vertex Pharmaceuticals Incorporated)
ONO-5532 Gel-One (Intra-articular injection)	Cross-linked hyaluronate	Knee osteoarthritis	P3	In-license (Japan) (Seikagaku Corporation)
		Hip osteoarthritis	P3	In-license (Japan) (Seikagaku Corporation)
ONO-2808 (Oral medication)	S1P5 receptor agonist	Multiple system atrophy	P3	In-house
BHV-1300 (Subcutaneous injection)	Immunoglobulin G (IgG) degrader	Graves' disease	P3	In-license (Japan, South Korea, Taiwan and ASEAN) (Biohaven)
DCC-3014 vimseltinib ROMVIMZA (Oral medication)	CSF-1R inhibitor	Tenosynovial giant cell tumor	P2（Japan）	In-house
		cGvHD	P2	In-house
ONO-2020 (Oral medication)	Epigenetic regulation	Alzheimer's disease	P2	In-house
		Agitation associated with dementia due to Alzheimer's disease	P2	In-house
ONO-1110 (Oral medication)	Endocannabinoid regulation	Postherpetic neuralgia	P2	In-house
		Fibromyalgia	P2	In-house
		Hunner type interstitial cystitis	P2	In-house
ONO-4915 (Subcutaneous injection)	PD-1×CD19 bispecific antibody	Sjögren's disease	P2	In-house

Development code Generic name Product name （Dosage form）	Pharmacological Action	Target indication (Combination drug)	Phase	In-house / In-license
ONO-4685 besufetamig (Intravenous injection)	PD-1×CD3 bispecific antibody	Autoimmune disease	P1	In-house
ONO-2416 (Oral medication)		Psychiatric disorders	P1	In-house
ONO-3310 (Oral medication)		Kidney diseases	P1	In-house
ONO-6414 (Oral medication)		Autoimmune disease	P1	In-house
ONO-3401 (Oral medication)		Neurological disorders	P1	In-house

The change from the announcement of financial results for the First quarter of the ended March 31, 2027, is as follows:

(Oncology)

Development code Generic name Product name （Dosage form）	Pharmacological Action	Target indication (Combination drug)	Development status or reason for termination
ONO-4578 (Oral medication)	Prostaglandin receptor (EP4) antagonist	Gastric cancer, First-line treatment (Standard treatment (combination with Opdivo and chemotherapy))	In August 2026, an international phase III clinical trial of ONO-4578 (a prostaglandin receptor (EP4) antagonist) in combination with Opdivo and chemotherapy was initiated for the treatment of gastric cancer.
ONO-4538/ Nivolumab / Opdivo (Intravenous injection)	A human anti-human PD-1 monoclonal antibody	Non-small cell lung cancer, neoadjuvant and adjuvant therapy (Combination with chemotherapy)	In August 2026, an application of combination therapy with Opdivo and chemotherapy was approved in South Korea and Taiwan for perioperative treatment of non-small cell lung cancer.
ONO-4538/ Nivolumab / Opdivo (Intravenous injection)	A human anti-human PD-1 monoclonal antibody	Hepatocellular carcinoma, adjuvant therapy	In September 2026, a phase III trial of Opdivo for adjuvant treatment of hepatocellular carcinoma was conducted. However, as the primary endpoint was not met, the development has been discontinued.
DCC-2618/ ripretinib/ QINLOCK (Oral medication)	KIT inhibitor	Gastrointestinal stromal tumor (GIST), Fourth-line treatment	In October 2026, an application of QINLOCK (KIT inhibitor) was approved in South Korea for the fourth-line treatment of gastrointestinal stromal tumor (GIST).
ONO-4578 (Oral medication)	Prostaglandin receptor (EP4) antagonist	Non-small cell lung cancer, Second-line treatment (in combination with Opdivo and standard chemotherapy)	In October 2026, we had been conducting a Phase I study of the prostaglandin receptor (EP4) antagonist ONO-4578 in combination with Opdivo and standard chemotherapy in patients with non-small cell lung cancer. However, development of this program was discontinued for strategic reasons.

(Areas Other than Oncology)

Development code Generic name Product name （Dosage form）	Pharmacological Action	Target indication (Combination drug)	Development status or reason for termination
ONO-2808 (Oral medication)	S1P5 receptor agonist	Multiple system atrophy	In August 2026, an international phase III clinical trial of ONO-2808 (an S1P5 receptor agonist) was initiated for the treatment of multiple system atrophy.
ONO-4915 (Subcutaneous injection)	PD-1×CD19 bispecific antibody	Sjögren's syndrome	In August 2026, phase II of ONO-4915 (PD-1×CD19 bispecific antibody) was initiated for the treatment of Sjögren's syndrome.
ONO-2017/ Cenobamate/ Excopri (Oral medication)	Inhibition of voltage-gated sodium currents / positive allosteric modulator of $GABA_A$ ion channel	Partial-onset seizures	In September 2026, Excopri, an inhibitor of voltage-gated sodium currents and a positive allosteric modulator of the $GABA_A$ ion channel, was approved in Japan for the treatment of partial-onset seizures in patients with epilepsy (including secondary generalized seizures).
ONO-1110 (Oral medication)	Endocannabinoid regulation	Depression / Social anxiety disorder	In October 2026, phase II of ONO-1110 (endocannabinoid modulator) was conducted in Japan for the treatment of depression and social anxiety disorder. However, as efficacy could not be confirmed, the development has been discontinued.
BHV-1300 (Subcutaneous injection)	Immunoglobulin G (IgG) degrader	Graves' disease	In October 2026, the Company entered into a licensing agreement with Biohaven for exclusive development and commercialization rights to its immunoglobulin G (IgG)-degrading assets in Japan, South Korea, Taiwan and ASEAN countries. BHV-1300 is currently undergoing a phase III clinical trial for the treatment of Graves' disease in the United States and other countries.

Profile for Main Development

Opdivo Intravenous Infusion (ONO-4538 / BMS-936558) / Nivolumab (injection)
Opdivo, a human anti-human PD-1 monoclonal antibody, is being developed for the treatment of various kinds of cancers, etc. PD-1 is a receptor expressed on the surface of activated lymphocytes and plays a role in a regulatory pathway that suppresses the activated lymphocytes in the body (negative signal). Research indicates that cancer cells exploit this pathway to escape from immune responses. Opdivo is thought to provide benefit by blocking PD-1-mediated negative regulation of lymphocytes, thereby enhancing the ability of the immune system to recognize cancer cells as foreign and eliminate them.
In Japan, South Korea, and Taiwan, Ono is co-developing this with Bristol-Myers Squibb Company. In the other areas, Bristol-Myers Squibb Company is developing this.

Yervoy Injection (ONO-4480) / Ipilimumab (injection)
Yervoy, a human anti-human CTLA-4 monoclonal antibody, is being developed for the treatment of various kinds of cancer.
In Japan, South Korea, and Taiwan, Ono is co-developing this with Bristol-Myers Squibb Company. In the other areas, Bristol-Myers Squibb Company is developing this.

ONO-4482 / BMS-986016 / relatlimab (injection)
ONO-4482, a human anti-human LAG-3 monoclonal antibody, is being developed for the treatment of melanoma.
In Japan, South Korea, and Taiwan, Ono is co-developing this with Bristol-Myers Squibb Company. In the other areas, Bristol-Myers Squibb Company is developing this.

ONO-4578 (oral)
ONO-4578, a Prostaglandin receptor (EP4) antagonist, is being developed for the treatment of gastric cancer, colorectal cancer, and Hormone receptor-positive, HER2-negative breast cancer.

Braftovi Capsules (ONO-7702) / Encorafenib (oral)
Braftovi, a BRAF inhibitor, has been marketed in Japan for the treatment of melanoma, and an additional indication was later approved in Japan and South Korea for the treatment of BRAF-mutant colorectal cancer. Additionally, we have obtained approval in Japan for the treatment of unresectable BRAF-mutant thyroid cancer and unresectable anaplastic BRAF-mutant thyroid cancer, in combination with Mektovi tablets after progression following cancer chemotherapy. In addition, approval has been obtained in South Korea for the treatment of unresectable advanced or recurrent colorectal cancer with BRAF mutations.

Velexbru Tablets (ONO-4059) / Tirabrutinib Hydrochloride (oral)
Velexbru, a BTK inhibitor, has been marketed in Japan for the treatment of recurrent or refractory primary central nervous system lymphoma, and additional indications were later approved for the treatment of waldenstrom macroglobulinemia and lymphoplasmacytic lymphoma. Additionally, applications were approved in South Korea and Taiwan for the treatment of recurrent or refractory B-cell primary central nervous system lymphoma. Furthermore, an application for approval has been filed in the United States for the treatment of primary central nervous system lymphoma. Velexbru is also being developed in Japan for the treatment of pemphigus.

ONO-4685 (injection)
ONO-4685, a PD-1 x CD3 bispecific antibody, is being developed for the treatment of autoimmune disease. In the oncology area, it is being developed in Japan and the USA for the treatment of T-cell lymphoma.

ONO-4538HSC (subcutaneous injection)
ONO-4538HSC, a combination drug comprising nivolumab and volhyaluronidase alfa, is being developed in Japan for the treatment of pediatric malignant solid tumors, epithelioid sarcoma, and solid tumors.

ONO-8250 (injection)
ONO-8250, an iPS cell-derived HER2-targeted CAR-T cell therapeutics, is being developed in the USA for the treatment of HER2-expressing solid tumor.

ONO-7427 (injection)
ONO-7427, an anti-CCR8 antibody, is being developed in Japan for the treatment of solid tumor.
In Japan, South Korea, and Taiwan, Ono is co-developing this with Bristol-Myers Squibb Company. In the other areas, Bristol-Myers Squibb Company is developing this.

ONO-7428 (injection)
ONO-7428, an anti-ONCOKINE-1 antibody, is being developed in Japan for the treatment of solid tumor.

ONO-0530 / sapablursen (subcutaneous injection)
ONO-0530, an antisense oligonucleotide targeting TMPRSS6, is being developed for the treatment of polycythemia vera.

Excopri (ONO-2017) / Cenobamate (Oral)
Excopri (ONO-2017), an inhibitor of voltage-gated sodium currents and a positive allosteric modulator of the $GABA_A$ ion channel, has been approved in Japan for the treatment of partial-onset seizures (including secondary generalized seizures). In addition, it is being developed in Japan for the treatment of partial-onset seizures (pediatric) and generalized tonic-clonic seizures.

ONO-2808 (oral)
ONO-2808, a S1P5 receptor agonist, is being developed in Japan, the USA, Europe and other regions for the treatment of multiple system atrophy.

ONO-2020 (oral)

ONO-2020, an epigenetic regulation, is being developed for the treatment of Alzheimer's disease in Japan and the USA, and for the treatment of agitation associated with dementia due to Alzheimer's disease in Japan.

ONO-1110 (oral)

ONO-1110, an endocannabinoid modulator, is being developed in Japan for the treatment of postherpetic neuralgia, fibromyalgia and interstitial cystitis/ bladder pain syndrome.

ONO-4915 (subcutaneous injection)

ONO-4915, a PD-1×CD19 bispecific antibody, is being developed in Japan for the treatment of Sjögren's disease.

QINLOCK (ripretinib) (oral)

QINLOCK is a KIT inhibitor that has been approved by the US FDA for the treatment of adult patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with three or more kinase inhibitors, including imatinib. It is based on the favorable results in fourth-line and fourth-line +GIST patients in the Phase 3 INVICTUS trial and has been approved in regions such as North America, Europe, and Australia. In October 2026, approval was obtained in South Korea, and the product is currently under regulatory review in Japan. In addition, it is being developed as a second-line treatment for patients with KIT exon 11+17/18 mutation-positive GIST.

ROMVIMZA (vimseltinib) (oral)

ROMVIMZA (DCC-3014), a CSF-1 receptor inhibitor, has been approved in the United States and Europe for the treatment of tenosynovial giant cell tumor (TGCT) and is also being developed in Japan. In addition, it is being developed in the United States for the treatment of chronic graft-versus-host disease (cGvHD).

DCC-3116 (inlexisertib) (oral)

DCC-3116, a ULK inhibitor, is being developed in combination with ripretinib for the potential treatment of solid tumor in the United States.

DCC-3009 (oral)

DCC-3009, a pan-KIT inhibitor, is being developed in the United States for the potential treatment of gastrointestinal stromal tumor.

ONO-8531 (povetacicept) (subcutaneous injection)

ONO-8531, BAFF/APRIL dual antagonist, is being developed for the treatment of multiple serious B-cell mediated diseases, including IgA nephropathy and primary membranous nephropathy.

ONO-5532 (Gel-One) (intra-articular injection)

ONO-5532 is an intra-articular injection containing cross-linked hyaluronic acid as its active ingredient. It has been marketed overseas since 2012 under the names "Gel-One®" in the United States and "HyLink®" in Taiwan and Italy. In Japan, it is being developed for the treatment of knee osteoarthritis and hip osteoarthritis.

DCC-2812 (oral)

DCC-2812, a GCN2 activation, is being developed for the treatment of renal cell carcinoma, urothelial carcinoma, and castration-resistant prostate cancer.

ONO-7429 (Injection)

ONO-7429, an anti-L1CAM ADC, is being developed for the treatment of solid tumor.

ONO-2416 (oral)

ONO-2416, an in-house drug, is being developed for the treatment of psychiatric disorder.

ONO-3310 (oral)

ONO-3310, an in-house drug, is being developed for the treatment of kidney disease.

ONO-6414 (oral)

ONO-6414, an in-house drug, is being developed for the treatment of autoimmune disease.

ONO-3401 (oral)

ONO-3401, an in-house discovered compound, is being developed for the treatment of neurological diseases.

BHV-1300 (subcutaneous injection)

BHV-1300 is an immunoglobulin G (IgG) degrader for which the Company has entered into a licensing agreement with Biohaven granting exclusive development and commercialization rights in Japan, South Korea, Taiwan and ASEAN countries. It is being developed for the treatment of Graves' disease.